Wells Fargo lowered the firm’s price target on Voyager Therapeutics (VYGR) to $12 from $14 and keeps an Overweight rating on the shares. With neuro tox uncovered for SOD1 program in NHPs, the key question is potential readthrough to TRACER platform. NHP data from the tau AAV program showed no neuro tox at doses corresponding to reasonable tau lowering, suggesting the platform is still viable, the firm notes.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VYGR:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue